CapMan sells its holding in Swereco Group
(Thomson Reuters ONE) -
CapMan Press Release - 2.10.2015 at 9.30 a.m. EEST
CapMan sells its holding in Swereco Group
Funds managed by CapMan have sold their holding in Swereco Group AB, a Swedish
manufacturer of OTC products, to Karo Bio AB (publ). The transaction was
completed on 1 October 2015.
"We are pleased with our investment in Swereco. During our ownership, Swereco
has completed several key acquisitions, brought new and interesting products and
designs to the OTC market and expanded sales to the other Nordic countries"
comments Johan Bennarsten, responsible for the CapMan Life Science IV fund.
Funds managed by CapMan, including the CapMan Life Science IV fund, invested in
Swereco AB in 2010 and owned 35.75% of the company's equity prior to the
transaction. CapMan Plc is a significant investor in the CapMan Life Science IV
fund.
For more information, please contact:
Johan Bennarsten, CapMan Life Science, tel. +46 707 495 659
CapMan www.capman.com
CapMan is one of the European leaders in the private equity industry. For more
than 25 years, we have been developing companies and real estate and supporting
their sustainable growth. We are committed to understanding the needs of our
customers in an ever-changing market environment. Our objective is to provide
attractive returns and innovative solutions for our investors and value adding
services for professional investment partnerships, growth-oriented companies and
tenants. Our entrepreneurial investment partnerships - Buyout, Real Estate,
Russia and Credit - as well as our associated company Norvestia are responsible
for investment activities and value creation. CapMan's service business offering
includes fundraising advisory services, purchasing activities and fund
management services to both internal and external customers. CapMan has 100
private equity professionals and assets under management of ?3.0 billion.
Swereco Group AB www.swerecogroup.com
Founded in 1973, Swereco develops and produces a range of products towards
pharmacies and OTC market. Swereco recorded net sales of approx. ?16.5 million
in 2014. The company's head office is in Stockholm with sales offices in Oslo
and Copenhagen. Its products are also distributed in Finland, Germany, the UK
and central Europe.
Karo Bio AB www.karobio.se
Karo Bio is a pharmaceutical company that develop drugs for key medical needs
and with the aim to create a balance between preclinical projects and products
and projects closer to the market. The headquarters are based in Huddinge and
the share is listed on Nasdaq Stockholm.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CapMan Oyj via GlobeNewswire
[HUG#1956277]
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2015 - 08:35 Uhr
Sprache: Deutsch
News-ID 424319
Anzahl Zeichen: 3411
contact information:
Town:
Helsinki
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CapMan sells its holding in Swereco Group"
steht unter der journalistisch-redaktionellen Verantwortung von
CapMan Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
